QUEBEC CITY, Sept. 1, 2011 /CNW/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that CEO Martin Driscoll will present at the 2011 BioPharm America Conference taking place September 7-9. Mr. Driscoll will provide an overview of Asmacure's nicotinic acetylcholine receptor technology, with emphasis on the company's lead product in development for the treatment of asthma, ASM-024. The presentation will be given on Friday, September 9, at 9:00 a.m. EDT in the Hancock room at the Westin Boston Waterfront Hotel in Boston, MA.
About Asmacure Ltee
Asmacure Ltee is a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases. The company's lead compound, ASM-024, is a novel molecular entity currently in clinical development for the treatment of asthma. ASM-024 utilizes Asmacure's proprietary technology comprised of nicotinic acetylcholine receptor agonists and is the first nicotinic receptor agonist in the clinic for this indication. Phase II proof-of-concept studies are ongoing to assess the anti-inflammatory, bronchodilating and bronchoprotective properties of ASM-024 administered by inhalation.
Asmacure is a privately held company located in Quebec City, Canada. The major investors in Asmacure include Domain Associates, Fonds Bio-Innovation and Innovatech Quebec. For more information visit www.asmacure.com
Media Contacts: Tiberend Strategic Advisors, Inc.(212) 827-0020, Andrew Mielach, email@example.comClaire Sojda, firstname.lastname@example.org
SOURCE Asmacure Ltee
For further information: Web Site: http://www.asmacure.com